Frazier Life Sciences Management, L.P. Eledon Pharmaceuticals, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.67 Billion
- Q4 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 1,176,735 shares of ELDN stock, worth $5.17 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
1,176,735Holding current value
$5.17 Million% of portfolio
0.29%Shares
1 transactions
Others Institutions Holding ELDN
# of Institutions
77Shares Held
37.2MCall Options Held
17KPut Options Held
2.7K-
Bvf Inc San Francisco, CA6.29MShares$27.6 Million0.96% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.57MShares$15.7 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.89MShares$12.7 Million0.0% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L32.55MShares$11.2 Million2.15% of portfolio
-
First Light Asset Management, LLC Edina, MN2.33MShares$10.2 Million0.93% of portfolio
About Eledon Pharmaceuticals, Inc.
- Ticker ELDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,756,800
- Market Cap $60.4M
- Description
- Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...